Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
- Global Phase 3 TOPAZ-1 study will evaluate the efficacy and safety of BIIB059, as compared to placebo,?in active?systemic lupus erythematosus (SLE),?a debilitating autoimmune disease?which has limited treatment options
- Positive Phase 2 LILAC study efficacy results support the further evaluation of BIIB059 in SLE
MEDIA CONTACT: Allison Parks +1 781 464 3260 public.affairs@biogen.com | INVESTOR CONTACT: Mike Hencke +1 781 464 2442 IR@biogen.com |